Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Advance Jr
NCT07194850Phase 3Recruiting
- Sponsor
- argenx
- Start
- Oct 2025
- Primary completion
- Oct 2028
- Modality
- Antibody Fragments
- Countries
- 10
01
Overview
A Phase 3 trial of efgartigimod alfa in immune thrombocytopenia (ITP), sponsored by argenx. Started Oct 2025; status: recruiting.
02
Drugs
efgartigimod alfa
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07194850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07194850.